Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Zamtocabtagene autoleucel |
Synonyms | |
Therapy Description |
Zamtocabtagene autoleucel (MB-CART2019.1) are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD19, potentially resulting in antitumor activity (Blood (2020) 136 (Supplement 1): 48). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Zamtocabtagene autoleucel | MBCART2019.1|MB CART2019.1|MB-CART2019.1 | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 | Zamtocabtagene autoleucel (MB-CART2019.1) are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both CD20 and CD19, potentially resulting in antitumor activity (Blood (2020) 136 (Supplement 1): 48). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04844866 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) | Active, not recruiting | SWE | POL | NLD | LTU | ITA | HUN | FRA | ESP | DEU | CZE | BEL | AUT | 0 |